Ozempic & Wegovy Gastroparesis Lawsuits

Patients who developed gastroparesis or severe gastrointestinal injuries after using Ozempic, Wegovy, or other GLP-1 drugs may qualify for compensation.

Filing Deadline

Filing Now

Settlement Info

869 lawsuits as of September 2024. Key Daubert hearing scheduled May 2025.

Overview

GLP-1 agonist medications like Ozempic and Wegovy, marketed for diabetes and weight loss, have been linked to severe gastrointestinal injuries including gastroparesis (stomach paralysis).

Key Facts

Active Cases: 869 lawsuits as of September 2024
Defendants: Novo Nordisk, Eli Lilly
Key Hearing: Daubert hearing May 2025
Primary Injuries: Gastroparesis, severe vomiting, intestinal blockage

Who Qualifies?

You may be eligible if you:

Used Ozempic, Wegovy, Mounjaro, or similar GLP-1 drugs
Developed gastroparesis or severe GI issues
Required hospitalization or surgery
Experienced persistent symptoms after stopping medication

Affected Medications

Ozempic (semaglutide)
Wegovy (semaglutide)
Mounjaro (tirzepatide)
Rybelsus (semaglutide)
Saxenda (liraglutide)

Common Injuries

Gastroparesis (stomach paralysis)
Severe nausea and vomiting
Intestinal blockage
Gallbladder disease
Bowel obstruction
Malnutrition and dehydration

Recent Developments

March 2025: 164 new cases added to GLP-1 MDL
May 2025: Critical Daubert hearing to determine expert testimony admissibility
Growing number of cases as more patients report injuries

How to File

If you or a loved one suffered serious side effects from these medications, contact us for a free case review.